Pharmacogenetic guidance for antiplatelet treatment.
Publication
, Journal Article
Jeong, Y-H; Bliden, KP; Park, Y; Tantry, US; Gurbel, PA
Published in: Lancet
August 25, 2012
Duke Scholars
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
August 25, 2012
Volume
380
Issue
9843
Start / End Page
725
Location
England
Related Subject Headings
- Purinergic P2Y Receptor Antagonists
- Precision Medicine
- Point-of-Care Systems
- Platelet Aggregation Inhibitors
- Male
- Humans
- Genetic Testing
- Genetic Carrier Screening
- General & Internal Medicine
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Jeong, Y.-H., Bliden, K. P., Park, Y., Tantry, U. S., & Gurbel, P. A. (2012). Pharmacogenetic guidance for antiplatelet treatment. Lancet, 380(9843), 725. https://doi.org/10.1016/S0140-6736(12)61398-1
Jeong, Young-Hoon, Kevin P. Bliden, Yongwhi Park, Udaya S. Tantry, and Paul A. Gurbel. “Pharmacogenetic guidance for antiplatelet treatment.” Lancet 380, no. 9843 (August 25, 2012): 725. https://doi.org/10.1016/S0140-6736(12)61398-1.
Jeong Y-H, Bliden KP, Park Y, Tantry US, Gurbel PA. Pharmacogenetic guidance for antiplatelet treatment. Lancet. 2012 Aug 25;380(9843):725.
Jeong, Young-Hoon, et al. “Pharmacogenetic guidance for antiplatelet treatment.” Lancet, vol. 380, no. 9843, Aug. 2012, p. 725. Pubmed, doi:10.1016/S0140-6736(12)61398-1.
Jeong Y-H, Bliden KP, Park Y, Tantry US, Gurbel PA. Pharmacogenetic guidance for antiplatelet treatment. Lancet. 2012 Aug 25;380(9843):725.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
August 25, 2012
Volume
380
Issue
9843
Start / End Page
725
Location
England
Related Subject Headings
- Purinergic P2Y Receptor Antagonists
- Precision Medicine
- Point-of-Care Systems
- Platelet Aggregation Inhibitors
- Male
- Humans
- Genetic Testing
- Genetic Carrier Screening
- General & Internal Medicine
- Female